Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%. SHANGHAI, March 27, 2025 ...

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Investment giant KKR & Co. Inc. (NYSE: KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth. In its “High Grading” Outlook for 2026, the ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

The fund has returned 49.96 percent over the past year, 20.43 percent over the past three years, 8.90 percent over the past five years, and 12.13 percent over the past decade.

Protagonist Therapeutics is a clinical-stage biotechnology company that uses proprietary peptide technology to address unmet medical needs in hematology and immunology. It focuses on patients with ...

This interactive course gives clinical affairs, regulatory and quality professionals a focused overview of EU IVDR 2017/746 performance study requirements for IVDs and companion diagnostics, with an ...